Viva Biotech Revenues Surge on Move Into Contract Drug Manufacturing

Two key acquisitions last fall helped fuel fivefold rise in first-half revenue, as company swung back into profitability Key Takeaways: Viva Biotech’s fivefold jump in first-half revenues and move back to profitability come on the back of its acquisition last year of two contract drug makers Company’s shift to contract drug making comes as global pharma firms shift focus to drug development By Richard Barbarossa A couple of recent acquisitions are proving strong tonic for Viva Biotech Holdings (1873.HK), a globally-focused Chinese provider of third-party pharmaceutical services for other drug…

Read MORE »

Biosimilar Specialist Henlius Takes Off. Now Comes the Hard Part

Fosun Pharma-backed company posts huge revenue jump in the second half of last year, as it boosts production and signs more global licensing deals to stay ahead of competition Key takeaways: Henlius is one of the earliest entrants to China’s young biosimilar market, giving it a first-mover advantage The company will need to quickly develop more new drugs, boost production and sign new partnerships to stay ahead in an increasingly crowded field By Richard Barbarossa Biosimilar specialist Shanghai Henlius Biotech, Inc. (HKEx: 2696) is set to ramp up production after…

Read MORE »

Burning Rock Builds Up Hospital Partner Pipeline as Losses Mount

Precision cancer diagnostics developer’s fourth-quarter revenue grew 50%, as two more of its key products moved closer to commercialization Key takeaways 1)  Burning Rock’s in-hospital business could post healthy growth in 2021 due to a strong pipeline of new partner hospitals for its cancer test kits. 2)  The company has engaged in preliminary discussions with China’s regulator for approval of its new test kits for six types of cancer, which could go on sale as soon as 2022. By Richard Barbarossa Burning Rock Biotech Ltd. (NASDAQ: BNR) posted a widening…

Read MORE »